GENPREX RSS Feed | Nachrichten - www.finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten BörsengeschehenFinanzenhttps://www.finanzen.netde-definanzen.net GmbHMon, 06 Apr 2026 06:38:35 +0200https://images.finanzen.net/images/finanzen_net_neu.gifGENPREX RSS Feed | Nachrichten - www.finanzen.nethttps://www.finanzen.netGenprex Provides Clinical Update on Diabetes Gene Therapy ProgramWed, 07 Jan 2026 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/genprex-provides-clinical-update-on-diabetes-gene-therapy-program-15398521

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies

AUSTIN, ...

]]>https://www.finanzen.net/nachricht/aktien/genprex-provides-clinical-update-on-diabetes-gene-therapy-program-15398521Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal StudiesTue, 06 Jan 2026 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/genprex-announces-positive-preliminary-preclinical-data-from-study-of-gpx-002-in-type-2-diabetic-animal-studies-15395008

Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates

GPX-002 ...

]]>https://www.finanzen.net/nachricht/aktien/genprex-announces-positive-preliminary-preclinical-data-from-study-of-gpx-002-in-type-2-diabetic-animal-studies-15395008Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung CancerMon, 24 Nov 2025 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/data-from-genprex-s-acclaim-1-phase-1-gene-therapy-clinical-trial-published-in-clinical-lung-cancer-15308433

Phase 1 Study in Non-Small Cell Lung Cancer Combined Reqorsa® Gene Therapy with Tagrisso®

AUSTIN, ...

]]>https://www.finanzen.net/nachricht/aktien/data-from-genprex-s-acclaim-1-phase-1-gene-therapy-clinical-trial-published-in-clinical-lung-cancer-15308433Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical TrialsWed, 19 Nov 2025 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/genprex-adds-clinical-trial-site-for-acclaim-1-and-acclaim-3-lung-cancer-clinical-trials-15291449

New Clinical Trial Site Added for Clinical Studies of Reqorsa® Gene Therapy to Treat Lung Cancer

Acclaim-1 and Acclaim-3 Clinical Trials ...

]]>https://www.finanzen.net/nachricht/aktien/genprex-adds-clinical-trial-site-for-acclaim-1-and-acclaim-3-lung-cancer-clinical-trials-15291449Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat CancersTue, 18 Nov 2025 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/genprex-announces-u-s-patent-for-reqorsa-gene-therapy-in-combination-with-pd-l1-antibodies-to-treat-cancers-15287483

Strengthens Intellectual Property Portfolio and Provides Protection for Therapeutic Combination in Acclaim-3 Clinical Trial

]]>https://www.finanzen.net/nachricht/aktien/genprex-announces-u-s-patent-for-reqorsa-gene-therapy-in-combination-with-pd-l1-antibodies-to-treat-cancers-15287483Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat CancerTue, 04 Nov 2025 13:00:00 +0100https://www.finanzen.net/nachricht/aktien/genprex-announces-european-patent-office-s-intent-to-grant-a-patent-for-the-combination-of-reqorsa-gene-therapy-and-pd-1-antibodies-to-treat-cancer-15184793

Adds to the Previously Granted Patents Covering the Use of REQORSA in Combination with Immune Checkpoint Inhibitors

Strengthens Patent ...

]]>https://www.finanzen.net/nachricht/aktien/genprex-announces-european-patent-office-s-intent-to-grant-a-patent-for-the-combination-of-reqorsa-gene-therapy-and-pd-1-antibodies-to-treat-cancer-15184793Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets...Tue, 28 Oct 2025 12:00:00 +0100https://www.finanzen.net/nachricht/aktien/genprex-collaborators-report-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-15131270

Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer

Combining REQORSA with ...

]]>https://www.finanzen.net/nachricht/aktien/genprex-collaborators-report-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets-15131270Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Tar...Thu, 23 Oct 2025 13:00:00 +0200https://www.finanzen.net/nachricht/aktien/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-tar-15110633

Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer

Research Suggests that ...

]]>https://www.finanzen.net/nachricht/aktien/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-tar-15110633Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Tar...Tue, 14 Oct 2025 13:00:00 +0200https://www.finanzen.net/nachricht/aktien/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-tar-15044067

Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer

]]>https://www.finanzen.net/nachricht/aktien/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-for-the-treatment-of-lung-cancer-at-the-2025-aacr-nci-erotc-international-conference-on-molecular-tar-15044067